Drug Profile
Research programme: ddRNAi therapeutics - Benitec Biopharma
Alternative Names: BB 501; Research programme: ddRNAi therapeuticsLatest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Benitec Biopharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Head and neck cancer; Solid tumours
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 28 Mar 2021 No recent reports of development identified for research development in Head-and-neck-cancer in USA
- 03 Feb 2017 Early research in Head and neck cancer in USA (unspecified route) before February 2017 (Benitec Biopharma pipeline, February 2017)